Abstract
Background:Treatment options for systemic sclerosis (SSc) remain limited especially in severe skin, lung and musculoskeletal involvements. B-cell targeted therapy with anti-CD20 Rituximab (RTX), is widely available, reports from case series...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have